Endocyte Annual Revenue, Competitors, Number of Employees and Funding
Estimated Revenue & Financials
- Endocyte's estimated annual revenue is currently $15.9M per year.
- Endocyte received $101.8M in venture funding in April 2014.
- Endocyte's estimated revenue per employee is $201,000
- Endocyte's total funding is $160M.
- Endocyte has 79 Employees.
- Endocyte grew their employee count by 20% last year.
- Endocyte currently has 1 job openings.
|Karen Hilbert||Manager, Financial Clinical Operations||Email Available|
|Iontcho Vlahov||Vp Discovery Chemistry||Email Available|
|Matthew Call||COO||Email Available|
|Lindsay Willard||Financial Planning Manager||Email Available|
|Ryan Dorton||Director, Discovery Operations||Email Available|
|Lisa Coy||Clinical Data Manager||Email Available|
|Sheila Swain||Associate Director Of Clinical Quality||Email Available|
|Anita Matthews||Clinical Quality Manager|
|Wendy Perez||Director of Clinical Operations at Endocyte, Inc.||Email Available|
|Beth Taylor||Vice President, Finance and Chief Accounting Officer|
What Is Endocyte?
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma.keywords:Biotechnology,Healthcare,Marketing,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|SSCI, a Divisio...||$8.6M||43||8%||N/A|
|MedScript LTC P...||$7.4M||37||28%||N/A|
Major Players in Cancer Tubulin Inhibitors Market are Abraxis Biosciences, Agensys, Amgen, Celgene, Eagle Pharmaceuticals, Endocyte, ...
The major player of the Cancer Tubulin Inhibitors market (Abraxis Biosciences, Agensys, Amgen, Celgene, Eagle Pharmaceuticals, Endocyte, ...
During his 16 year tenure at Endocyte, he had responsibility for all business development and strategic transactions and led a variety of ...
|2004-12-07||$23.0M||C-2||Burrill and Company||Article|
|2008-02-06||$15.0M||Undisclosed||Oxford Finance Corp, GE Healthcare Financial Servic||Article|
|2009-10-19||$26.0M||C||Sanderling Ventures, Burrill & Company||Article|
|2010-09-01||$15.0M||Undisclosed||MidCap Financial, Silicon Valley Bank||Article|
|2014-03-27||$Undisclosed||Undisclosed||Credit Suisse Securities (USA) LLC||Article|
Endocyte Executive Hires
|2012-07-27||David Meek||Chief Commercial Officer||Article|
|2013-04-26||Torsten Hoof||VP/General Manager Europe||Article|
|2013-05-08||Scot L. Harper||VP Clinical Operations||Article|
|2015-04-08||David Mozley||VP Imaging||Article|
|2017-02-22||Michael Andriole||Chief Financial Officer||Article|